At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication. The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/20 | $150,500,000 | Series A |
Hudson Bay Capital Management Johnson & Johnson Development Corporation (JJDC) Lilly Asia Ventures RA Capital Management Vivo Capital | undisclosed |
